A Phase 3b/4, Open-label Study to Assess the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Previously Vaccinated Adults Aged ≥18 Years

The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults.

开始日期2024-09-09

申办/合作机构

ModernaTX, Inc.

NCT05387317

/ Withdrawn临床3期

A Randomised Controlled Trial to Assess the Immunogenicity, Safety & Reactogenicity of Standard Dose Versus Fractional Doses of COVID-19 Vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) Given as a Booster Dose After Priming With Coronavac or AstraZeneca in Healthy Adults in Indonesia

This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either AstraZeneca or Coronavac as their primary doses.
Both fractional and standard doses of Pfizer-BioNTech, AstraZeneca and Moderna will be tested.

开始日期2024-04-01

申办/合作机构

Murdoch Childrens Research Institute

[+4]

PACTR202212801139469

/ Suspended临床2期

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age

开始日期2023-08-01

申办/合作机构-

100 项与艾拉索米瑞相关的临床结果

登录后查看更多信息

100 项与艾拉索米瑞相关的转化医学

登录后查看更多信息

100 项与艾拉索米瑞相关的专利（医药）

登录后查看更多信息

2,551

项与艾拉索米瑞相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents

Article

作者: Powell, Richard ; Boone, Gary ; Ali, Kashif ; Etokhana, Kenneth ; Clifford, Robert ; Figueroa, Amparo L. ; Miller, Jacqueline ; Rizzardi, Barbara ; Ampajwala, Madhavi ; Girard, Bethany ; Weiner, Leonard ; Slobod, Karen ; Kirstein, Judith ; Yeakey, Anne ; Carr, Quito ; Segall, Nathan ; Fierro, Carlos ; Elfaki, Salma ; Xu, Wenqin ; Akinsola, Adebayo ; Berman, Gary ; Chu, Laurence ; Ohnmacht, Richard ; Reyes-Acuna, Celia ; Turner, Mark ; Buynak, Robert ; Ruiz-de-Luzuriaga, Katherine ; Matherne, Paul ; Jeanfreau, Robert ; Priddy, Frances ; Das, Rituparna ; Deng, Weiping ; Griffin, Carl ; Adetona, Olutola

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427). Binding antibody (bAb) responses against SARS-CoV-2 variants of interest and COVID-19 incidence after vaccination were also evaluated. Median boosting interval was 315 days. The mRNA-1273 booster was well-tolerated, with an acceptable safety profile. Relative to pre-booster, nAb geometric mean levels increased after the booster by 17.8-fold and 4.7-fold among pre-booster SARS-CoV-2-negative and -positive participants, respectively. Effectiveness was successfully inferred based on noninferiority of nAb levels from mRNA-1273 booster dose (Day 29) compared with nAb levels after mRNA-1273 primary series (Day 57) among young adults in COVE. Further, the booster increased bAb levels relative to pre-booster baseline against SARS-CoV-2 variants (alpha [B.1.1.7], beta [B.1.351], gamma [P.1], and delta [B.1.617.2]), regardless of pre-booster SARS-CoV-2 status. COVID-19 incidence (cases per 1000 person-months) was lower among boosted (0 cases) than non-boosted (95.766 cases) participants in January 2022, a peak period during the early omicron transmission. In summary, the mRNA-1273 50-μg booster induced robust nAb responses in previously vaccinated adolescents, regardless of SARS-CoV-2 serostatus. Effectiveness was successfully inferred and the booster was well-tolerated, with no new safety concerns identified.

2025-12-31·ANNALS OF MEDICINE

Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

Article

作者: Syu, Guan-Da ; Kuo, Kuang-Che ; Weng, Ken-Pen ; Kuo, Ho-Chang ; Priyambodo, Seto ; Liu, Shih-Feng

BACKGROUND:

Vaccination is one of the best ways to control the SARS-CoV-2 outbreak. In Taiwan, healthcare workers were prioritized for vaccination, but the effectiveness of these vaccines for them remains unclear. Thus, it's essential to examine their neutralizing antibodies after prime-boost vaccinations.

METHODS:

In this prospective observational study, 514 healthcare workers from Chang Gung Memorial hospitals in Taiwan were included between 19 March 2021 and 21 August 2021. The two doses of COVID-19 vaccines were either a match or a mixing of AZD1222 and mRNA-1273, e.g. AZD1222 + AZD1222 (n = 406), mRNA-1273 + mRNA-1273 (n = 62), and AZD1222 + mRNA-1273 (n = 46). Blood specimens were drawn after two doses of vaccines, defined as post-vaccine days [median 34.00 days and interquartile range (IQR) 29.00-42.00 days], and examined for the neutralizing antibodies via SARS-CoV-2 neutralization kits. The results were analyzed as a percentage of inhibition based on the negative control.

RESULTS:

After 2 vaccination doses, subjects with AZD1222 + mRNA-1273 (median 97.15%, IQR 96.06-98.06%) and mRNA-1273 + mRNA-1273 (median 97.47%, IQR 96.75-97.89%) exhibited higher neutralizing antibodies than those receiving AZD1222 + AZD1222 vaccines (median 71.28%, IQR 49.39-89.70%) (the percentage was referred to inhibition of surrogate virus). The post-vaccination days negatively impacted the neutralizing antibodies, except for the mRNA-1273 + mRNA-1273 group. The presence of fever, headache, and myalgia after the second dosage was reflected in the higher neutralizing antibodies (median of no fever 76.00% vs. fever 97.00%, p < 0.0001; median of no headache 76.00% vs. headache 95.00%, p < 0.0001; median of no myalgia 75.50% vs. myalgia 96.00%, p < 0.0001). The subjects with underlying diseases, including hypertension and cancer showed lower neutralizing antibodies (median of no hypertension 81.00% vs. hypertension 56.00%, p = 0.0029; median of no cancer 81.00% vs. cancer 56.00%, p = 0.0143).

CONCLUSION:

Heterologous prime-boost vaccines (AZD1222 + mRNA-1273) and two doses of mRNA vaccines are recommended. For future directions, we need to investigate the effectiveness of the vaccination against new SARS-CoV-2 variants.

2025-12-01·IMMUNOLOGIC RESEARCH

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

Review

作者: Michos, Athanasios ; Kourlaba, Georgia ; Dourdouna, Maria-Myrto

A systematic review and meta-analysis were performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON SARS-CoV-2 interferon-γ release assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS, and medRxiv databases, to identify studies reporting the QuantiFERON SARS-CoV-2 (Starter (two antigen tubes) or Starter + Extended Pack (three antigen tubes), cut-off ≥ 0.15 IU/mL) positivity rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Programme Tool. A meta-analysis was conducted using a random-effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-73 vaccinated immunocompetent participants) were identified. For COVID-19-naïve participants, ≤ 3 months after the second dose, the pooled PR (random-effects model) was 86 (95% confidence interval (95% CI) 78-95%). Comparing the Starter vs. the Starter + Extended Pack, a significant difference in PRs was detected (80.6% vs. 100% p-value < 0.001). At 3-6 and >6 months after the second dose and ≥ 3 months after the third dose, the pooled PRs were 59% (95% CI 45-72%), 79% (95% CI 66-92%), and 66% (95% CI 50-82%), respectively. For convalescent participants, ≥ 6 months after the third dose, the pooled PR was 81% (95% CI 67-95%). Limitations include heterogeneity and a small number of studies, at some timepoints. In conclusion, following the second or third COVID-19 mRNA vaccine dose, QuantiFERON SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees, possibly because of waning immunity, reduced assay sensitivity, or lack of T-cell response induction in some vaccinees. The detection of positive responses was higher when the Starter + Extended Pack was used. PROSPERO Registration Number: CRD42023431315.

1,086

项与艾拉索米瑞相关的新闻（医药）

2025-04-10

·生物制品圈

深度剖析 mRNA 疫苗：设计原理、制造工艺与抗疫实战

摘要：mRNA 疫苗在应对新冠疫情中展现出重要价值，其快速的研发和生产能力令人瞩目。本文将详细介绍 mRNA 疫苗的设计原理、制造过程、作用机制，以及在新冠疫苗研发中的应用和面临的挑战，并探讨其未来发展方向，帮助读者全面了解这一前沿疫苗技术。一、mRNA 疫苗：疫苗领域的新希望传统疫苗在应对一些疾病时存在生产周期长、效果有限等问题。mRNA 疫苗则具有独特优势，它能快速设计和生产，可针对新兴病原体迅速做出反应，并且安全性良好，引发的免疫反应也很强大。新冠疫情期间，mRNA 疫苗如 Comirnaty 和 Spikevax 的成功研发和广泛应用，极大地推动了这一领域的发展。接下来，让我们深入了解 mRNA 疫苗的方方面面。二、mRNA 疫苗的设计与优化策略mRNA 疫苗主要分为自我扩增型（SAM 或 saRNA）疫苗和传统非复制型 mRNA 疫苗（原文图 1A、B 展示两种疫苗结构）。它们都包含 5’- 帽结构、非翻译区（UTRs）、开放阅读框（ORF）和聚 A 尾等关键元件，对这些元件进行优化能提升疫苗性能。5’- 帽的关键作用与优化：5’- 帽结构对于 mRNA 的稳定性、防止被核酸外切酶降解以及启动翻译至关重要。它还能帮助 mRNA 逃避先天免疫识别。在生产 IVT mRNA 时，常用 CleanCap 等进行加帽，其加帽效率高且能直接形成 cap-1 结构，可减少生产复杂性。不过，加帽过程中产生的未加帽转录本可能引发免疫反应，因此 IVT 后进行磷酸酶处理很有必要（结合图 1D 说明加帽相关内容）。UTRs 的调控作用及优化策略：UTRs 分为 5’-UTR 和 3’-UTR，它们对翻译效率有着重要影响。5’-UTR 帮助核糖体结合启动翻译，但过长的富含 GC 序列或复杂二级结构会起抑制作用；3’-UTR 则影响 mRNA 的稳定性、定位和翻译。优化 UTRs 可通过选用高表达人类基因的 5’-UTR，如 α - 珠蛋白的 5’-UTR；利用随机 UTR 文库和 SELEX 技术筛选优良的 3’-UTR 等方法实现。ORF 的优化要点：优化 ORF 可提高翻译效率，通过选择细胞 tRNA 频繁识别的同义密码子，能加快翻译速度、增加蛋白表达。但翻译速度过快可能导致蛋白折叠异常，所以有时需要引入稀有密码子来控制翻译节奏。此外，调整 ORF 的 GC 含量也能提升 mRNA 稳定性和翻译效率。如今，人工智能在优化 ORF 序列方面发挥着重要作用，可降低尿苷含量、增加 GC 含量，改善 mRNA 性能。聚 A 尾的重要性与添加方式：聚 A 尾能增强 mRNA 的稳定性、翻译效率和体内半衰期。它与多聚腺苷酸结合蛋白（PABP）相互作用，对翻译起始十分关键。一般认为 120 个核苷酸长度的聚 A 尾对 IVT mRNA 疫苗较为理想。添加聚 A 尾的方法有在 DNA 模板中编码和转录后用多聚腺苷酸聚合酶添加两种，前者是常用方法，但在质粒扩增时可能存在稳定性问题；后者虽能产生不同长度的聚 A 尾，且成本高、耗时久，但也有其应用场景。三、mRNA 疫苗的制造过程1.mRNA 的体外合成：mRNA 疫苗生产始于体外转录（IVT），以 DNA 模板合成 mRNA 。质粒 DNA（pDNA）因适合大规模生产、成本低且诱变风险小，常被用于大规模 mRNA 生产。转录时需加入核糖核苷酸、RNA 聚合酶（如 T7 RNA 聚合酶）等，同时采用优化 T7 RNA 聚合酶、控制核苷酸浓度等策略，可提高 IVT mRNA 的产量和翻译效率。2.mRNA 的纯化：IVT 后，mRNA 需要纯化，去除残留的反应成分，尤其是双链 RNA（dsRNA），因为它会激活先天免疫反应、抑制蛋白表达。常用的纯化方法包括氯化锂沉淀、酚 - 氯仿萃取、离子交换色谱等。在符合 GMP 标准的生产中，更倾向使用快速蛋白液相色谱（FPLC）或高效液相色谱（HPLC）。此外，还有利用乙醇缓冲液结合纤维素柱的低成本大规模纯化方法3.mRNA 的递送系统：裸露的 mRNA 难以穿过细胞膜，且易被 RNase 降解，直接注射还会引发过度的先天免疫激活，因此需要有效的递送系统（原文图 3，展示不同的 mRNA 递送方法）。脂质纳米颗粒（LNPs）：LNPs 是目前最有效的 mRNA 递送载体，被广泛应用于已获批的新冠 mRNA 疫苗中。它由可电离脂质、中性辅助脂质、聚乙二醇（PEG）和胆固醇组成（结合图 4 介绍 LNPs 的成分）。可电离脂质在低 pH 值下带正电，有助于 mRNA 的包封和内体逃逸；PEG 可防止纳米颗粒聚集，减少与血清蛋白的相互作用；胆固醇维持脂质层的完整性。mRNA 通过微流体混合或乙醇加载等方法被包裹在 LNPs 中，形成的 mRNA-LNP 制剂经冻干处理可提高热稳定性。其他递送策略：除 LNPs 外，还有基于聚合物的递送系统，如早期使用的二乙氨基乙基葡聚糖和常用于 saRNA 疫苗的聚乙烯亚胺（PEI）；阳离子肽如鱼精蛋白，可保护 mRNA 但可能影响蛋白表达；以树突状细胞为靶点的递送策略主要用于癌症疫苗开发。4.mRNA 疫苗的给药途径：mRNA 疫苗的给药途径会影响蛋白表达和免疫反应。常见的给药途径包括皮内注射、肌肉注射和皮下注射（可结合相关研究数据，说明不同途径的优缺点）。皮内注射能引发较强的抗体反应，但存在局部副作用且注射体积受限；皮下注射因皮下免疫细胞较少，效果相对较弱；肌肉注射是目前最常用的给药途径，尤其是在新冠疫苗接种中，它可支持较大的注射体积，副作用相对较少。四、mRNA 疫苗激活免疫系统的机制激活适应性免疫系统：mRNA 疫苗通过 LNPs 进入宿主细胞后，经内吞作用进入细胞，然后从内体逃逸并被核糖体翻译为抗原蛋白。这些抗原蛋白可被 B 细胞识别，引发抗体反应；也可被抗原呈递细胞（APCs）摄取，通过 MHC II 类分子呈递给 CD4+ T 细胞，激活细胞免疫反应；还能被蛋白酶体降解为肽段，经 MHC I 类分子呈递给 CD8+ 细胞毒性 T 细胞，从而产生细胞免疫和体液免疫反应（原文图 6A，直观展示适应性免疫反应过程）。激活先天免疫系统及应对策略：外源性 mRNA，包括 IVT mRNA 疫苗，可被模式识别受体（PRRs）识别，引发先天免疫反应，如产生干扰素、炎症反应和激活 APCs 。虽然这种 “自我佐剂” 特性有助于增强免疫反应，但也可能导致 mRNA 降解和翻译抑制，降低疫苗效力，还可能引发如发热、寒战、恶心等副作用，在年轻人群中甚至可能出现严重过敏反应（如心肌炎）。为解决这些问题，可采用修饰核苷酸（如假尿苷、5 - 甲基胞苷等）降低免疫原性，提高体内半衰期和蛋白表达；使用 FPLC、HPLC 等纯化方法去除 dsRNA；对残留的未加帽 mRNA 进行磷酸酶处理等策略。五、mRNA 疫苗佐剂的应用佐剂可增强疫苗的免疫原性，虽然目前仅有少数被批准用于人类，但 mRNA 疫苗自身具有一定的自我佐剂特性，额外添加佐剂可进一步提升其效果。例如，将获批的 MF59 加入阳离子纳米乳液中，可改善 saRNA 疫苗的性能；环二聚腺苷单磷酸（c - di - AMP）能增强流感 saRNA 疫苗的免疫原性。此外，疫苗递送载体如 RNActive 平台中的鱼精蛋白，以及 LNPs 本身，都可作为佐剂，诱导强烈的 T 辅助 1（Th1）T 细胞反应。六、新冠 mRNA 疫苗的研发与应用新冠 mRNA 疫苗候选产品对比：新冠疫情期间，多种 mRNA 疫苗被研发出来（插入原文表 3，详细对比各新冠 mRNA 疫苗候选产品）。mRNA-1273：由 Moderna 开发，是一种核苷修饰的 mRNA 疫苗，包裹在 LNPs 中，编码带有两个脯氨酸替代的全长刺突蛋白（S2P），能稳定蛋白的预融合构象。临床前研究显示其在小鼠体内可诱导高滴度的中和抗体，临床试验中预防症状性 COVID-19 的有效率达 94.1% 。BNT162b2：由 BioNTech 和 Pfizer 联合研发，同样是核苷修饰、LNP 包裹的 mRNA 疫苗，编码全长稳定的 S - 2P 。在临床前研究中，它在小鼠和恒河猴体内诱导出了强大的抗体反应和 T 细胞激活，临床试验中预防 COVID-19 的有效率高达 95%，成为首个获得 FDA 批准的新冠 mRNA 疫苗。CVnCoV：CureVac AG 开发的未修饰 mRNA 疫苗，虽然在临床前研究中能诱导小鼠和仓鼠产生病毒中和滴度和 T 细胞反应，但在 III 期临床试验中有效率仅为 48.2%，低于其他修饰的 mRNA 疫苗，最终开发终止。ARCoV：由 Walvax 研发，编码刺突蛋白的受体结合域（RBD），具有热稳定性，可在室温下保存至少一周。在临床试验中，它能诱导产生中和抗体，但因使用未修饰的核糖核苷酸，导致发热等不良事件发生频率较高，目前已获得印度尼西亚的紧急使用授权。saRNA - 基于的新冠疫苗候选产品：自我扩增型 RNA（saRNA）疫苗也是新冠疫苗研发的方向之一。COVAC1：由伦敦帝国理工学院开发，编码 S - 2P 蛋白，通过 LNPs 递送。在小鼠实验中能诱导出较强的免疫反应，但在人体 I 期试验中，免疫原性低于预期，可能是由于物种间免疫复杂性的差异。ARCT - 021：Arcturus Therapeutics 公司的产品，编码全长非突变刺突蛋白，使用 STARR 技术和 LUNAR 纳米颗粒。在 I 期试验中耐受性良好，II 期试验显示出剂量依赖性的抗体反应。基于此平台改进的 ARCT - 154 成为首个在日本获批的 saRNA 疫苗，对预防严重 COVID - 19 的有效率达 95.3% 。针对变异株的新冠 mRNA 疫苗：SARS - CoV - 2 不断变异，出现了如 Beta、Gamma、Delta 和 Omicron 等变异株，这些变异株的出现降低了现有疫苗的效力。为应对这一问题，研发了针对变异株的 mRNA 疫苗（结合表 4，分析不同变异株对疫苗效力的影响）。例如，Moderna 的 mRNA - 1273.214 等多价疫苗，针对原始毒株和 Omicron 变异株 BA.1 的刺突蛋白，能提供更广泛的保护；Pfizer - BioNTech 的 Comirnaty XBB.1.5 针对 XBB.1.5 变异株，可诱导出针对该变异株及相关 Omicron 亚变异株的强中和抗体反应。广谱新冠 mRNA 疫苗：为了应对不断出现的变异株，科学家们致力于研发能提供更广泛保护的广谱 mRNA 疫苗。例如，通过删除 S 蛋白中 RBD 和 S2 结构域的糖基化位点，暴露保守表位，增强对多种变异株的免疫反应；将多个变异株的关键突变整合到疫苗抗原中，如 RQ3013 和 NVSI - 06 - 09 等疫苗，在临床前或临床试验中展现出对多种变异株的有效保护。七、下一代 mRNA 疫苗：联合 mRNA 疫苗随着新冠病毒新变异株的出现和免疫力的减弱，人们需要像接种流感疫苗一样定期接种新冠疫苗。为了简化免疫接种流程，联合 mRNA 疫苗应运而生。例如，Pfizer - BioNTech 探索将其针对 Omicron 变异株的二价新冠疫苗与四价基于 modRNA 的流感疫苗相结合；Abogen Biosciences 将其新冠 mRNA 疫苗 ARCOV 与流感 mRNA 疫苗 ARIAV 联合，在临床前研究中显示出对流感病毒和 SARS - CoV - 2 共感染的有效保护；Moderna 也在开发针对Moderna 也在开发针对 COVID - 19、流感和呼吸道合胞病毒（RSV）的三合一 mRNA 疫苗，有望通过一次接种预防三种主要的呼吸道疾病。这些联合疫苗策略充分展示了 mRNA 疫苗在控制多种病毒方面的潜力。八、mRNA 疫苗的未来展望mRNA 疫苗在多个领域展现出了巨大的发展潜力。在递送系统方面，LNPs 将不断优化，以提高稳定性、实现靶向递送，并探索如冻干和化学修饰等替代冷藏的储存方法，同时新型递送平台如口服剂型和植物源囊泡也在逐步兴起。在应用范围上，mRNA 疫苗不仅在传染病防治领域发挥重要作用，还在癌症免疫治疗（如针对常见 KRAS 突变的疫苗和 HPV 相关肿瘤疫苗）和自身免疫性疾病治疗（通过调节调节性 T 细胞实现免疫平衡）等方面不断拓展。此外，多价 mRNA 疫苗能够结合多种抗原表位，为应对快速变异的病原体提供更广泛的保护；个性化疫苗则根据个体的基因和免疫特征定制，进一步提高疫苗的有效性和安全性。在剂量研究方面，科研人员致力于找到既能激活免疫反应又能减少副作用的最佳剂量，同时提高全球疫苗可及性的工作也在推进，包括技术转让、在低收入地区建立本地生产能力以及优化物流配送等。人工智能技术的应用将加速 mRNA 疫苗的设计过程，通过优化稳定性、密码子使用和结构完整性等方面，助力开发出更高效的疫苗。九、总结BNT162b2 和 mRNA - 1273 等 mRNA 疫苗在抗击新冠疫情中取得了显著成效，但在优化使用和提高可及性方面仍面临挑战。例如，部分不良反应如心肌炎等可能与高剂量有关，优化剂量有望降低这些风险；mRNA 疫苗对超低温储存的要求限制了其在一些地区的分发，不过 LNP 配方和稳定剂的改进正在逐步提高疫苗在较高温度下的稳定性；此外，高昂的成本也阻碍了低收入国家对疫苗的获取，需要进一步降低生产成本和优化制造工艺。随着 SARS - CoV - 2 的持续变异，研发针对变异株的多价和广谱疫苗至关重要。联合 mRNA 疫苗为预防多种呼吸道疾病提供了便利，但公众对 mRNA 疫苗的接受度仍有待提高。随着更多关于 mRNA 疫苗有效性和安全性数据的公布，公众的接受度有望像在新冠疫情期间一样逐渐增加（原文图 8，展示全球新冠 mRNA 疫苗的接种情况，直观呈现公众对疫苗的接受趋势）。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

信使RNA疫苗

2025-04-07

·生物制品圈

疫苗新突破：一文读懂自我扩增 RNA（saRNA）疫苗

摘要：本文介绍了自我扩增 RNA（saRNA）疫苗的研究进展。saRNA 疫苗是新兴疫苗技术，具有诸多优势。文中阐述了其基于甲病毒的载体设计、作用机制，以及在研发过程中在载体设计、递送系统方面的进展，通过临床评估展现了其免疫原性和安全性。同时探讨了面临的挑战及解决策略，展望了在传染病防治和癌症免疫治疗等领域的应用前景。一、疫苗新势力：自我扩增 RNA（saRNA）疫苗登场在疫苗领域，自我扩增 RNA（saRNA）疫苗正逐渐崭露头角。它是一种新兴的疫苗技术，和传统的 mRNA 疫苗相比，有着独特的优势。世界卫生组织强调免疫接种的重要性，目前全球针对多种病原体研发了不同的疫苗平台，核酸疫苗在其中占比逐渐增加。在抗击新冠疫情中，mRNA 疫苗发挥了重要作用，但它也有一些不足，比如抗原表达时间较短。而saRNA 疫苗可以通过在细胞内自我扩增，实现较低剂量下的高效抗原表达，免疫原性更强，成本效益也更高。就像已获批的 KostaiveⓇ疫苗，只需较低剂量就能发挥作用，这充分展示了saRNA 疫苗的潜力。二、探秘 saRNA 疫苗的核心机制与设计saRNA 疫苗的工作原理：saRNA 疫苗的载体主要来源于甲病毒，像委内瑞拉马脑炎病毒（VEEV）、辛德毕斯病毒（SINV）和塞姆利基森林病毒（SFV）。这些甲病毒经过改造，去除了致病部分，保留了能让 RNA 自我复制的能力。（此处插入原文图 1A，展示甲病毒改造及 saRNA 复制机制）当saRNA进入细胞后，会利用甲病毒的复制机制，大量生成自身的拷贝以及编码抗原的亚基因组 mRNA，从而持续表达抗原，激活人体的免疫系统。精心设计的载体：在saRNA 疫苗的研发过程中，载体设计至关重要。从体外转录环节开始，就要考虑如何提高产量和质量。例如，调整镁离子和醋酸根离子浓度、控制反应温度等可以优化转录效果。5’帽结构对于saRNA的稳定性和翻译效率十分关键，目前有多种方法来实现有效的加帽。（此处插入原文关于 5’帽结构相关的示意图，辅助理解加帽过程及作用）同时，对非编码区（UTR）和编码序列的优化也在不断探索中，通过这些优化可以增强saRNA的复制能力和抗原表达水平。此外，saRNA还能实现多基因表达，通过添加额外的亚基因组启动子、2A 肽或内部核糖体进入位点（IRES）等，能同时表达多种抗原，为开发多价疫苗提供了可能。三、攻克递送难题：让 saRNA 疫苗精准发挥作用saRNA本身是带负电的大分子，直接注射难以进入细胞发挥作用，所以需要借助合适的递送系统。目前，多种纳米颗粒被用于saRNA 疫苗的递送。（图2，展示不同纳米颗粒的结构及递送原理）脂质纳米颗粒（LNPs）：这是目前应用较广的一种递送载体。像 ComirnatyⓇ、SpikevaxⓇ等疫苗都采用了这种技术。LNPs 由多种成分组成，比如可电离脂质、磷脂、胆固醇和聚乙二醇（PEG）脂质等。这些成分各自发挥作用，可电离脂质在低 pH 值时能与saRNA结合，磷脂维持颗粒稳定性，胆固醇帮助颗粒与细胞融合，PEG 脂质则控制颗粒大小和延长半衰期。不过，LNPs 也存在一些问题，比如会在肝脏和脾脏等非靶器官分布，可能导致毒性反应，还可能引发免疫反应。其他纳米颗粒：除了 LNPs，还有阳离子纳米乳液、聚合物纳米颗粒和脂质复合物等也可用于saRNA的递送。阳离子纳米乳液如用于 HIV 疫苗和新冠疫苗（GEMCOVACⓇ）的递送，展现出了一定的安全性和免疫原性。聚合物纳米颗粒由阳离子聚合物与saRNA结合形成，虽然有些聚合物存在细胞毒性，但也有一些经过改进后能有效递送saRNA并引发免疫反应。脂质复合物则是由阳离子脂质与核酸形成的复合物，不同的脂质复合物在疫苗递送中各有特点。四、saRNA 疫苗的临床 “成绩单”：以新冠疫苗为例新冠疫情期间，众多saRNA 疫苗开展了临床试验。（此处插入原文关于新冠 saRNA 疫苗临床试验相关的表格，呈现不同疫苗的试验信息）其中，ARCT - 021 和 ARCT - 154 等疫苗备受关注。ARCT - 021 疫苗在首次接种后有免疫原性，但第二次接种未显示出增强效果。而 ARCT - 154 疫苗通过优化抗原和载体设计，在接种后，参与者体内产生了较高水平的中和抗体。不同疫苗的临床试验对比发现，saRNA 疫苗的甲病毒 backbone（如 VEEV 的不同变体）可能会影响血清转化水平。此外，saRNA 疫苗在异源初免 - 加强接种策略中表现出色，能诱导出较强的 T 细胞反应和持久的抗体水平，相比 mRNA 加强疫苗，其抗体衰减速度更慢。五、saRNA 疫苗面临的挑战与应对之策1.安全性考量：虽然saRNA 疫苗在临床试验中总体安全性良好，常见的不良反应多为注射部位的轻微反应和一些全身症状，且严重反应罕见，但由于其基于病毒衍生的基因组，仍需进行严格的安全性评估。（图3，展示外源性 RNA 诱导的先天免疫激活过程，辅助理解安全性问题的产生机制）2.先天免疫反应问题：人体的免疫系统会识别外来的 RNA，从而引发先天免疫反应，这可能影响saRNA的稳定性和翻译，甚至导致细胞凋亡。为了解决这个问题，研究人员采用了多种方法。比如使用经过修饰的核苷酸，像 5 - 羟甲基胞苷（hm5C）、5 - 甲基胞苷（m5C）或 5 - 甲基尿苷（m5U）等，这些修饰可以降低免疫反应，同时提高saRNA的转染效率和免疫原性。（图 4A，展示不同修饰核苷酸对 saRNA 的影响）此外，对saRNA进行纯化，去除转录过程中产生的双链 RNA 等副产物，也能减少免疫反应。还有利用先天免疫抑制剂，如一些小分子、肽或病毒蛋白，来抑制免疫反应，增强saRNA的表达。3.其他挑战及解决办法：saRNA 疫苗还面临着一些其他挑战，比如 RNA - LNP 平台的稳定性问题，saRNA与天然病毒发生重组的潜在风险等。针对稳定性问题，研究人员通过优化储存条件，如在特定浓度的蔗糖溶液中储存，或开发具有热稳定性的阳离子脂质纳米载体等方法来解决。对于重组风险，虽然目前证据显示风险较低，但仍需进一步研究，开发低重组可能性的saRNA载体库是降低风险的有效策略。六、saRNA 疫苗的未来蓝图：不止于传染病防治saRNA 疫苗在传染病防治领域展现出了巨大的潜力，随着技术的不断优化，它有望在全球疫苗接种计划中发挥更重要的作用，尤其是在资源有限的地区，其低成本、高效能的特点更具优势。而且，saRNA 疫苗的应用不仅仅局限于传染病。在癌症免疫治疗方面，它也展现出了良好的前景。通过编码肿瘤相关抗原，saRNA 疫苗可以激活人体的免疫系统，识别和攻击癌细胞。不过，要实现更广泛的应用，还需要进一步研究解决一些关键问题，比如修饰核苷酸对复制酶活性的影响、抗复制酶免疫的水平和类型，以及saRNA长期复制的影响等。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗信使RNA

2025-04-07

·investors.modernatx.com

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025. Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases. COVID-19 Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation Presenter: Frances Priddy Session: Advances in vaccine effectiveness for viral respiratory infections Date: April 12 | Time & Location: 11:00 (Hall 9) Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation Presenter: Spyros Chalkias Session: Vaccines and prophylaxis against respiratory viral infections Date: April 13 | Time & Location: 11:00 (Hall 9) Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation Presenter: Spyros Chalkias Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall) Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation Presenter: Christina Grassi Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall) Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation Presenter: Frances Priddy Session: Advances in vaccine effectiveness for viral respiratory infections Date: April 12 | Time & Location: 11:00 (Hall 9) Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation Presenter: Spyros Chalkias Session: Vaccines and prophylaxis against respiratory viral infections Date: April 13 | Time & Location: 11:00 (Hall 9) Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation Presenter: Spyros Chalkias Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall) Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation Presenter: Christina Grassi Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall) RSV Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation Presenter: Mihir Desai Session: On the frontiers of vaccine-driven prevention Date: April 12 | Time & Location: 08:30 (Arena 1) Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation Presenter: Mihir Desai Session: Clinical Trials Date: April 15 | Time & Location: 12:00 (Poster Hall) Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation Presenter: Clarisse Demont Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation Presenter: Simon De Lusignan Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation Presenter: Mihir Desai Session: On the frontiers of vaccine-driven prevention Date: April 12 | Time & Location: 08:30 (Arena 1) Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation Presenter: Mihir Desai Session: Clinical Trials Date: April 15 | Time & Location: 12:00 (Poster Hall) Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation Presenter: Clarisse Demont Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation Presenter: Simon De Lusignan Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Mpox Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation Presenter: Hiwot Hiruy Session: Novel vaccines in clinical development Date: April 14 | Time & Location: 17:30 (Hall 3) Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation Presenter: Hiwot Hiruy Session: Novel vaccines in clinical development Date: April 14 | Time & Location: 17:30 (Hall 3) Cytomegalovirus Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation Presenter: Ben Lorenz Session: Clinical Trials Date: April 15 | Time & Location: 12:00 (Poster Hall) Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation Presenter: Ben Lorenz Session: Clinical Trials Date: April 15 | Time & Location: 12:00 (Poster Hall) Influenza Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation Presenter: Mieke Soens Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation Presenter: Mieke Soens Session: Influenza and respiratory viruses Date: April 12 | Time & Location: 12:00 (Poster Hall) Norovirus Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation Presenter: Mark A. Schmidt Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology Date: April 12 | Time & Location: 12:00 (Poster Hall) Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation Presenter: Mark A. Schmidt Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology Date: April 12 | Time & Location: 12:00 (Poster Hall) About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna's vaccine candidates to alleviate disease outcomes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Luke Mircea-Willats Senior Director, International Communications Luke.Mirceawillats@modernatx.com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com SOURCE: Moderna Inc.

疫苗临床结果临床2期信使RNA

100 项与艾拉索米瑞相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾拉索米瑞	J07	DB15654

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒“奥密克戎”变异株感染	英国	Moderna, Inc.	2022-08-15
新型冠状病毒感染	加拿大	Moderna, Inc.	2020-12-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
严重急性呼吸综合征	临床2期	美国	ModernaTX, Inc.	2022-09-30
流感病毒感染	临床2期	美国	ModernaTX, Inc.	2022-05-13
免疫抑制	临床2期	美国	ModernaTX, Inc.	2022-03-10
肺移植排斥反应	临床2期	美国	ModernaTX, Inc.	2022-03-10
巨细胞病毒感染	临床1期	美国	ModernaTX, Inc.	2022-05-24
呼吸道合胞体病毒感染	临床1期	美国	ModernaTX, Inc.	2022-05-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05280158 (CTgov)	临床1/2期	肺移植排斥反应 \| 免疫抑制	19	mRNA-1273 (Moderna COVID-19 vaccine) (Standard-dose)	襯襯壓鑰鑰獵齋衊鹽淵 = 鑰積觸獵夢積襯齋夢襯鹽衊膚網製艱製鑰鏇襯 (廠願衊齋觸窪網製鏇觸, 艱顧顧夢繭淵夢製鏇鏇 ~ 選鏇夢鹹繭壓醖餘積築) 更多	-	2025-03-26
				mRNA-1273 (Moderna COVID-19 vaccine) (Mid-Dose)	襯襯壓鑰鑰獵齋衊鹽淵 = 膚憲製淵憲製壓壓糧選鹽衊膚網製艱製鑰鏇襯 (廠願衊齋觸窪網製鏇觸, 鏇獵鬱築鬱選衊衊廠廠 ~ 鏇鏇繭願網築簾鬱願夢) 更多
NCT05022329 (BOOST KIDNEY, CTgov)	临床2/3期	新型冠状病毒感染 \| 慢性肾病，V期 \| 慢性肾病	273	BNT162b2 (Third Dose BNT162b2)	鹽廠窪鏇蓋簾齋鹹鹹繭(廠糧衊獵糧夢繭艱鏇顧) = 糧糧繭鑰糧膚範衊簾艱觸淵積壓顧構壓糧顧齋 (構獵鹹遞遞積糧糧窪艱, 0.334) 更多	-	2025-02-19
				mRNA-1273 (Moderna) (Third Dose mRNA-1273)	鹽廠窪鏇蓋簾齋鹹鹹繭(廠糧衊獵糧夢繭艱鏇顧) = 鏇餘鏇繭製艱積願窪鬱觸淵積壓顧構壓糧顧齋 (構獵鹹遞遞積糧糧窪艱, 0.169) 更多
NCT05047770 (Pubmed) 人工标引	临床3期	带状疱疹	497	mRNA-1273quFlu D-QIVt influenza vaccine (QIV)	夢範襯願壓獵網衊獵範(選範積襯鑰願鬱獵顧襯) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. 鏇繭膚鹹鏇襯選願簾餘 (築鑰鏇鹽夢願鹽鹽艱顧 ) 更多	非劣	2024-12-31
				mRNA-1273 + Flu D-QIV(CoAd )
NCT05228730 (MIACoV, CTgov)	临床3期	新型冠状病毒感染	13	Tozinameran (Standard Pfizer-BioNTech Booster Group)	齋糧窪壓獵鬱襯製齋衊(獵製鑰積襯鏇鹽繭廠齋) = 製糧餘襯蓋鑰積餘蓋窪糧構廠齋願憲壓簾繭糧 (積膚餘網鏇淵憲艱觸網, 壓糧築醖膚範網選網積 ~ 鹹積範簾艱繭簾鹽顧齋) 更多	-	2024-12-16
				Tozinameran - fractional dose (Fractional Pfizer-BioNTech Booster Group)	齋糧窪壓獵鬱襯製齋衊(獵製鑰積襯鏇鹽繭廠齋) = 齋壓淵壓願壓蓋窪製鑰糧構廠齋願憲壓簾繭糧 (積膚餘網鏇淵憲艱觸網, 餘獵鹽選鬱壓廠鏇鏇觸 ~ 繭糧廠淵齋構觸衊網廠) 更多
NCT05249829 (CTgov)	临床2/3期	新型冠状病毒感染	3,548	mRNA-1273.529 (Part 1: mRNA-1273.529)	醖膚繭憲簾壓夢淵網願(願築蓋衊醖築鬱獵膚艱) = 遞觸鏇積膚願憲製衊鹹齋廠範窪醖膚齋繭選廠 (範鹽蓋夢糧窪蓋夢夢醖, 範構範夢艱繭餘鏇餘壓 ~ 選獵遞艱獵選獵繭鹽鏇) 更多	-	2024-08-09
				mRNA-1273 (Part 1: mRNA-1273)	醖膚繭憲簾壓夢淵網願(願築蓋衊醖築鬱獵膚艱) = 積蓋餘繭遞獵夢窪構築齋廠範窪醖膚齋繭選廠 (範鹽蓋夢糧窪蓋夢夢醖, 膚願鹹鹹衊繭衊鑰餘獵 ~ 廠遞壓範襯艱夢築淵廠) 更多
NCT04792567 (AMA-VACC, CTgov)	临床4期	继发进展型多发性硬化	41	BAF312+BNT162+mRNA-1273 (Siponimod - Continuous)	廠衊夢蓋憲構積鬱製夢 = 糧夢願廠艱齋網鑰鏇廠襯鏇糧顧繭襯顧製鏇遞 (鬱餘膚選觸繭鏇糧鬱獵, 鏇襯鹽鬱遞獵構鹹觸鏇 ~ 壓鑰觸鑰齋鹹蓋鏇鏇網) 更多	-	2024-05-17
				BAF312+BNT162+mRNA-1273 (Siponimod- Interrupted)	廠衊夢蓋憲構積鬱製夢 = 顧膚蓋鏇艱獵簾觸鏇鏇襯鏇糧顧繭襯顧製鏇遞 (鬱餘膚選觸繭鏇糧鬱獵, 製簾餘範鬱衊壓築窪壓 ~ 憲餘齋鬱製鏇衊鑰製鏇) 更多
NCT05375838 (CTgov)	临床1/2期	新型冠状病毒感染 \| 流感病毒感染	550	placebo+mRNA-1273 (mRNA-1273 + Placebo)	糧製齋鏇襯觸製鹽淵醖 = 醖餘襯網獵衊範窪壓築鏇齋繭壓鬱壓範餘醖積 (鏇選製艱膚選蓋製選醖, 構夢範積觸觸壓夢艱願 ~ 艱鑰壓簾鬱餘夢蓋選獵) 更多	-	2024-02-28
				placebo+mRNA-1010 (mRNA-1010 + Placebo)	糧製齋鏇襯觸製鹽淵醖 = 積構鬱窪襯築繭遞糧糧鏇齋繭壓鬱壓範餘醖積 (鏇選製艱膚選蓋製選醖, 觸選窪鬱齋淵鏇繭鹹觸 ~ 鬱夢鏇糧構艱積膚齋艱) 更多
EHA2023	N/A	-	49	MRNA-1273 SARS-COV-2 VACCINE (Recently transplanted patients (RTP))	願簾鏇築齋鑰鬱壓簾構(艱窪繭獵艱夢醖鹽顧壓) = 醖糧鏇積糧廠鬱醖鏇鹹製繭壓醖繭構鏇築構願 (餘膚遞鬱艱齋製憲積簾 ) 更多	-	2023-06-08
				MRNA-1273 SARS-COV-2 VACCINE (Long-term transplanted patients (LTTP))	願簾鏇築齋鑰鬱壓簾構(艱窪繭獵艱夢醖鹽顧壓) = 鏇齋糧選範衊艱淵簾蓋製繭壓醖繭構鏇築構願 (餘膚遞鬱艱齋製憲積簾 ) 更多
ARVO2023	N/A	视网膜血管阻塞	1,250	BNT162b2(Pfizer-BioNTech)	淵夢壓餘憲顧憲網衊齋(醖廠窪觸夢鏇襯顧鏇範) = 鏇鏇築糧範廠廠網憲壓襯觸襯廠築選襯鑰願膚 (壓鏇鑰餘廠餘遞憲膚獵 )	积极	2023-06-01
				SARS-CoV-2 vaccine (mRNA-1273(Moderna))	淵夢壓餘憲顧憲網衊齋(醖廠窪觸夢鏇襯顧鏇範) = 鹽積鏇觸網膚製觸鹹鬱襯觸襯廠築選襯鑰願膚 (壓鏇鑰餘廠餘遞憲膚獵 )